THE SCRIPPS RESEARCH INSTITUTE
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1924-12-11
- Employees
- 1K
- Market Cap
- -
- Website
- https://powermom.scripps.edu
Clinical Trials
30
Active:1
Completed:19
Trial Phases
4 Phases
Phase 1:10
Phase 2:15
Phase 4:2
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (28 trials with phase data)• Click on a phase to view related trials
Phase 2
15 (53.6%)Phase 1
10 (35.7%)Phase 4
2 (7.1%)Not Applicable
1 (3.6%)CLF065 for Chronic Pouchitis
- First Posted Date
- 2025-11-07
- Last Posted Date
- 2025-11-10
- Lead Sponsor
- Calibr, a division of Scripps Research
- Target Recruit Count
- 20
- Registration Number
- NCT07226050
The MagnaSafe-2 Registry: Assessing the Risks of Magnetic Resonance Imaging in Three Patient Groups
Not yet recruiting
- Conditions
- PacemakersMRI ImagingImplantable Cardioverter Defibrillator (ICD)
- First Posted Date
- 2025-09-24
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- The Scripps Research Institute
- Target Recruit Count
- 1500
- Registration Number
- NCT07189728
A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases
Phase 1
Not yet recruiting
- Conditions
- Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Idiopathic Inflammatory Myopathy (IIM)
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Calibr, a division of Scripps Research
- Target Recruit Count
- 12
- Registration Number
- NCT06913608
Long Term Follow-up Study for Subjects Administered CLBR001
- Conditions
- Long Term Follow-Up
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Calibr, a division of Scripps Research
- Target Recruit Count
- 40
- Registration Number
- NCT06882317
- Locations
- 🇺🇸
Virtual Research Group- Premier Research, Morrisville, North Carolina, United States
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
Phase 1
Recruiting
- Conditions
- Breast Cancer MetastaticLocally Advanced Breast Cancer (LABC)Malignant Neoplasm of BreastTriple Negative Breast Cancer (TNBC)Hormone Receptor-Positive Breast CancerHER2 + Breast Cancer
- Interventions
- Biological: Two Component Product CLBR001 + ABBV-461
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-09-17
- Lead Sponsor
- Calibr, a division of Scripps Research
- Target Recruit Count
- 20
- Registration Number
- NCT06878248
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
Rosemary-Derived Compound Shows Promise as Potential Alzheimer's Treatment in Preclinical Study
Researchers at The Scripps Research Institute have developed diAcCA, a stable derivative of carnosic acid found in rosemary and sage, which enhanced memory and brain density in mouse models of Alzheimer's disease.